Drugs / AV-101
AV-101
Trials 7 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT05280054 | Dec 2021 → Sep 2022 | — | VistaGen Therapeutics, Inc. | Unknown | No outcome recorded |
| Phase 1 | NCT01483846 | Dec 2011 → Sep 2012 | neuropathy, painful | VistaGen Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03583554 | Sep 2018 → Oct 2019 | — | Marijn Lijffijt, PhD | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT04147949 | Aug 2022 → Dec 2023 | Parkinson disease, drug-induced dyskinesia | VistaGen Therapeutics, Inc. | Unknown | No outcome recorded |
| Phase 2 | NCT03078322 | Mar 2018 → Oct 2019 | major depressive disorder | VistaGen Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT02484456 | Oct 2015 → Feb 2019 | major depressive disorder | National Institute of Mental Health (NIMH) | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT05557942 | Nov 2022 → Aug 2024 | pulmonary arterial hypertension | Aerovate Therapeutics | Terminated | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 10 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AV-101 | “Antidepressant Effects of the Glycine Receptor Antagonist AV-101 (4-chlorokynurenine) in Major Depressive Disorder” NCT02484456 ↗ |
| Known as | 4-Chlorokynurenine | “4-Chlorokynurenine (4-Cl-KYN, AV-101) is a prodrug of a NMDA receptor antagonist and is in clinical development for potential CNS indications.” PMID 38261609 ↗ Jan 20242“Antidepressant Effects of the Glycine Receptor Antagonist AV-101 (4-chlorokynurenine) in Major Depressive Disorder” NCT02484456 ↗ “AV-101 (4-chlorokynurenine, 4-Cl-KYN), an oral prodrug of 7-chlorokynurenic acid (7-Cl-KYNA)” PMID 33318635 ↗ Dec 2020 |
| Known as | 4-Cl-KYN | “4-Chlorokynurenine (4-Cl-KYN, AV-101) is a prodrug of a NMDA receptor antagonist and is in clinical development for potential CNS indications.” PMID 38261609 ↗ Jan 20241“AV-101 (4-chlorokynurenine, 4-Cl-KYN), an oral prodrug of 7-chlorokynurenic acid (7-Cl-KYNA)” PMID 33318635 ↗ Dec 2020 |
| Known as | imatinib | “AV-101 (imatinib) administered via dry powder inhalation” NCT05557942 ↗ |
| Known as | L-4-chlorokynurenine | “the antidepressant effects of AV 101 (L-4-chlorokynurenine or 4-Cl- KYN) in MDD; this is a synthetic compound which is enzymatically converted into the selective glycine/NMDAR...” NCT02484456 ↗1“A novel oral prodrug, AV-101 (l-4 chlorokynurenine), which, in the brain, is converted into one of the most potent and selective GlyB site antagonists of the NMDAR” PMID 29229209 ↗ Jun 2017 |
| Action | Inhibit | “glycine receptor antagonist AV-101” NCT02484456 ↗ |
| Modality | Small molecule | “this is a synthetic compound” NCT02484456 ↗ |
| Route | Oral | “AV-101 or placebo were administered orally daily for 14 consecutive days” PMID 29229209 ↗ Jun 2017 |